Oligosaccharide composition is similar in drusen and dense deposits in membranoproliferative glomerulonephritis type II

Kidney International

Volumn 75, Issue 8, 2009, Pages 824-827

  D'souza, Yvonne B ^a   Jones, Carolyn J P ^b   Short, Colin D ^c   Roberts, Ian S D ^d   Bonshek, Richard E ^a,c  

^a MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Dense deposit disease; Drusen; Membranoproliferative glomerulonephritis; Oligosaccharides

Indexed keywords

GALACTOSE; GLYCOPEPTIDASE; LECTIN; MANNOSE; N ACETYLGLUCOSAMINE; OLIGOSACCHARIDE; SIALIC ACID; SIALIDASE;

ADULT; AGED; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENSE DEPOSIT DISEASE; DRUSEN; GLYCOSYLATION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEIN BINDING; RETINA MACULA AGE RELATED DEGENERATION;

EYE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; LECTINS; MACULAR DEGENERATION; NEURAMINIDASE; OLIGOSACCHARIDES;

EID: 63949084160     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.658     Document Type: Article

References (19)

1. Smith RJH, Alexander J, Barlow PN et al. New approaches to treatment of dense deposit disease. J Am Soc Nephrol 2007; 18: 2447-2456.
2. Alpers CE. Membranoproliferative glomerulonephritis. In: Kumar V, Abbas AK, Fausto N (eds). Robbins and Cotran Pathologic Basis of Disease, 7th edn. Elsevier Saunders: Philadelphia, 2005, pp 984-986.
3. Appel G, Terence Cook H, Hageman G et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16: 1392-1403.
4. Kathuria P. Last update 2006. Membranoproliferative glomerulonephritis. Available online at url: http://www.emedicine.com.
5. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 2004; 83: 18-34.
6. Duvall-Young J, MacDonald MK, McKechnie NM. Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol 1989; 73: 297-302.
7. Hageman GS, Luthert PJ, Chong VNH et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20: 705-732.
8. Leys A, Vanrenterghem Y, Damme BV et al. Fundus changes in membranoproliferative glomerulonephritis type II. A fluorescein angiographic study of 23 patients. Graefes Arch Clin Exp Ophthalmol 1991; 229: 406-410.
9. McAvoy CE, Silvestri G. Retinal changes associated with type 2 glomerulonephritis. Eye 2005; 19: 985-989.
10. Zipfel PF, Heinen S, Jozsi M et al. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97-106.
11. Abrera-Abeleda MA, Nishimura C, Smith JLH et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006; 43: 582-589.
12. Johnson LV, Leitner WP, Staples MK et al. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res 2001; 73: 887-896.
13. Leathem AJC, Atkins NJ. Lectin binding to paraffin sections. In: Bullock GR, Petrusz P (eds). Techniques in Immunocytochemistry, vol. 2, Academic Press: London, 1983, pp 39-70.
14. D'souza Y, Jones CJ, Bonshek RE. Glycoproteins of drusen and drusen-like lesions. J Mol Histol 2008; 39: 77-86.
15. Nevins TE. Lectin binding in membranoproliferative glomerulonephritis. Evidence for N-acetylglucosamine in dense intramembranous deposits. Am J Pathol 1985; 118: 325-330.
16. Solis D, Feizi T, Yuen C et al. Differential recognition by conglutinin and mannan-binding protein of N-glycans presented on neoglycolipids and glycoproteins with special reference to complement glycoprotein C3 and ribonuclease B. J Biol Chem 1994; 269: 11555-11562.
17. Hageman GS, Anderson DH, Johnson LV et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227-7232.
18. Zipfel PF, Heinen S, Jozsi M et al. Defective alternate pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97-106.
19. Anderson DH, Ozake S, Nealon M et al. Expression and localisation of apolipoprotein E in the neural retina and retinal pigment epithelium: implications for drusen formation and the pathogenesis of age-related macular degeneration. Am J Ophthalmol 2001; 131: 767-781.